The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Strong Auvelity Sales And Alzheimer's Label Hopes [Yahoo! Finance]
Axsome Therapeutics (NASDAQ:AXSM) had its price target raised by analysts at Jefferies Financial Group Inc. from $200.00 to $245.00. They now have a "buy" rating on the stock.
Axsome Therapeutics (AXSM) Reports 66% Revenue Growth in FY2025, Beats Analyst Estimates [Yahoo! Finance]
Axsome Therapeutics (NASDAQ:AXSM) had its "buy" rating reaffirmed by analysts at TD Cowen.
Axsome Therapeutics (NASDAQ:AXSM) had its price target raised by analysts at Leerink Partners from $150.00 to $205.00. They now have an "outperform" rating on the stock.